• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Can sacubitril/valsartan become the promising drug to delay the progression of chronic kidney disease?

作者信息

Chen Yang, Guo Lu-Ying, Zhao Ling-Fei, Ma Yan-Hong, Zhu Xue-Ling, Xu Ying, Chen Jiang-Hua

机构信息

Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China.

The Third Grade Laboratory under the National State, Administration of Traditional Chinese Medicine, Zhejiang, China.

出版信息

J Geriatr Cardiol. 2020 Dec 28;17(12):782-786. doi: 10.11909/j.issn.1671-5411.2020.12.002.

DOI:10.11909/j.issn.1671-5411.2020.12.002
PMID:33424946
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7762693/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4928/7762693/d6e36a58deee/jgc-17-12-782-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4928/7762693/d6e36a58deee/jgc-17-12-782-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4928/7762693/d6e36a58deee/jgc-17-12-782-1.jpg

相似文献

1
Can sacubitril/valsartan become the promising drug to delay the progression of chronic kidney disease?沙库巴曲缬沙坦能否成为延缓慢性肾脏病进展的有前景药物？
J Geriatr Cardiol. 2020 Dec 28;17(12):782-786. doi: 10.11909/j.issn.1671-5411.2020.12.002.
2
Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.《沙库巴曲缬沙坦（LCZ696）的临床药代动力学：一种新型血管紧张素受体-脑啡肽酶抑制剂》勘误
Clin Pharmacokinet. 2018 Jan;57(1):105-123. doi: 10.1007/s40262-017-0558-9.
3
Prevention against renal damage in rats with subtotal nephrectomy by sacubitril/valsartan (LCZ696), a dual-acting angiotensin receptor-neprilysin inhibitor.沙库巴曲缬沙坦（LCZ696），一种双重作用的血管紧张素受体脑啡肽酶抑制剂，对大鼠肾大部切除术后肾损伤的预防作用
Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.336.
4
Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data.沙库巴曲缬沙坦治疗心力衰竭的心血管结局：新出现的临床数据
Ther Clin Risk Manag. 2020 Aug 4;16:715-726. doi: 10.2147/TCRM.S234772. eCollection 2020.
5
6
The effects of sacubitril/valsartan and ramipril on the male fertility in hypertensive rats.沙库巴曲缬沙坦和雷米普利对高血压大鼠雄性生育能力的影响。
North Clin Istanb. 2020 Aug 5;7(5):425-432. doi: 10.14744/nci.2020.30906. eCollection 2020.

引用本文的文献

1
Sacubitril/valsartan in a wide spectrum of heart failure patients (from mechanisms of action to outcomes in specific populations).沙库巴曲缬沙坦用于广泛的心力衰竭患者（从作用机制到特定人群的治疗结果）。
Heart Fail Rev. 2025 Mar;30(2):387-405. doi: 10.1007/s10741-024-10471-1. Epub 2025 Jan 7.
2
The Effect of Sacubitril/Valsartan Treatment on Cardiac and Renal Functions of a Patient With Cardiorenal Syndrome Type 4 and Stage 5 CKD After More Than Three Years of Follow-Up.沙库巴曲缬沙坦治疗对一名4型心肾综合征合并5期慢性肾脏病患者心脏和肾功能的影响：三年多随访结果
Front Med (Lausanne). 2022 Mar 11;9:817833. doi: 10.3389/fmed.2022.817833. eCollection 2022.

本文引用的文献

1
Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction.血管紧张素-脑啡肽酶抑制剂在射血分数保留的心力衰竭中的肾脏结局。
Circulation. 2020 Sep 29;142(13):1236-1245. doi: 10.1161/CIRCULATIONAHA.120.047643. Epub 2020 Aug 17.
2
Effects of Angiotensin-Neprilysin Inhibition in Canines with Experimentally Induced Cardiorenal Syndrome.血管紧张素-脑啡肽酶抑制剂在犬实验性心肾综合征中的作用。
J Card Fail. 2020 Nov;26(11):987-997. doi: 10.1016/j.cardfail.2020.08.009. Epub 2020 Aug 22.
3
LCZ696 mitigates diabetic-induced nephropathy through inhibiting oxidative stress, NF-κB mediated inflammation and glomerulosclerosis in rats.
LCZ696通过抑制大鼠氧化应激、NF-κB介导的炎症反应和肾小球硬化来减轻糖尿病诱导的肾病。
PeerJ. 2020 Jun 19;8:e9196. doi: 10.7717/peerj.9196. eCollection 2020.
4
Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial.血管紧张素受体脑啡肽酶抑制与个体化肾素-血管紧张素-醛固酮系统阻断：PARALLAX试验的设计与原理
ESC Heart Fail. 2020 Jun;7(3):856-864. doi: 10.1002/ehf2.12694. Epub 2020 Apr 15.
5
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.血管紧张素-中性肽链内切酶抑制在射血分数保留的心力衰竭中的应用
N Engl J Med. 2020 Mar 19;382(12):1180. doi: 10.1056/NEJMc2000284.
6
Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology.2019 年心力衰竭临床实践更新：药物治疗、程序、设备和患者管理。欧洲心脏病学会心力衰竭协会专家共识会议报告。
Eur J Heart Fail. 2019 Oct;21(10):1169-1186. doi: 10.1002/ejhf.1531. Epub 2019 Aug 30.
7
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.血管紧张素-脑啡肽酶抑制剂在急性失代偿性心力衰竭中的应用。
N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11.
8
Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.沙库巴曲缬沙坦与厄贝沙坦对慢性肾脏病患者的影响。
Circulation. 2018 Oct 9;138(15):1505-1514. doi: 10.1161/CIRCULATIONAHA.118.034818.
9
Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.心力衰竭中血管紧张素-脑啡肽酶抑制的肾脏效应及相关结局。
JACC Heart Fail. 2018 Jun;6(6):489-498. doi: 10.1016/j.jchf.2018.02.004. Epub 2018 Apr 11.
10
LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD.LCZ696（沙库巴曲/缬沙坦）在慢性肾脏病中除了具有血管紧张素受体阻断作用外，还能减轻氧化应激、炎症和纤维化，并改善肾功能。
Am J Transl Res. 2017 Dec 15;9(12):5473-5484. eCollection 2017.